Subheading 9817.00.96, HTSUS; Negative Pressure Wound Therapy Pump
No Headquarters ruling in this index revokes or modifies this ruling. That is not confirmation that it is still in effect: this index does not hold every Headquarters ruling. Confirm its current status with CBP before relying on it (ruling on CBP CROSS). Text last read from CBP on Nov 21, 2026.
Ruling text
This is in response to your request, on behalf of Solventum Corporation (“Solventum”), dated August 20, 2025, for a binding ruling regarding the eligibility of Negative Pressure Wound Therapy Pumps (“NPWT Pumps”), namely the 3M™ ActiV.A.C.™ Therapy System, the 3M™ ActiV.A.C.™ Therapy System with iOn Progress™ Remote Therapy Monitoring, and the 3M™ V.A.C. Simplicity Therapy System, for subheading 9817.00.96, Harmonized Tariff Schedule of the United States (“HTSUS”), treatment.
A meeting was held on April 15, 2026, and additional information was submitted April 23, 2026. Our ruling is set forth below. FACTS: NPWT Pumps are medical device systems with specially manufactured parts, including specialized canisters, tubes, foams, adhesive drapes, and SensaT.R.A.C. pads that deliver negative pressure to draw wound edges together, remove exudate and infectious materials, promote granulation tissue formation, prepare the wound bed for closure, and reduce edema.
Solventum’s website states that “[t]he V.A.C. Therapy System is an integrated wound management system for use in acute and extended care settings… [the] System is designed for patients with chronic, acute, traumatic, subacute and dehisced wounds, partial-thickness burns, ulcers (such as diabetic or pressure) flaps and grafts.”1 The listing for the 3M™ ActiV.A.C.™ Therapy Unit also states that “[it] is an integrated wound management system for use in acute, extended[,] and home care settings.”2 1 https://www.solventum.com/en-us/home/f/b5005265195/ 2 https://www.solventum.com/en-us/home/f/b5005265184/ 2 Solventum is the parent company of U.S. importers KCI Imports, Inc. and KCI USA, Inc. (“affiliates”).
The affiliates will act as the importers of record of the Pumps. Solventum states that NPWT Systems have been effective at managing recurring wounds in patients with diabetes, COPD, end stage renal disease, quadriplegia, and paraplegia. Solventum also states that the NPWT Systems do not stop the recurrence of wounds or cure underlying disabilities and that the Pumps are portable and designed to be carried in a case.
According to articles from the National Institutes of Health and other NPWT System producers, “[NPWT] is primarily utilized to treat complex wounds which are non-healing or at risk of non-healing, such as diabetic foot ulcers or skin grafts.”3 “NPWT can be used for the treatment of a variety of wound types if assessed to be appropriate. It can be used in chronic or acute wounds, as well as open or closed wounds.
Some examples include: diabetic/neuropathic ulcers, pressure ulcers, chronic wounds, acute wounds, and dehisced wounds. Healthcare providers often treat chronic wounds that leave the wounds susceptible to infection.”4 “NPWT is often administered for weeks, but it could be used for months.
The text above is an excerpt. The official ruling, with its letterhead, signature and any attachments, is on CBP CROSS (H352973).